Dermatology · 7 h ago
Ruxolitinib Cream Improves Cutaneous Lichen Planus Outcomes in Phase 2 Trial
A randomized, double-blind phase 2 trial of 64 adults found that ruxolitinib 1.5% cream improved skin clearance and itch compared with vehicle at 16 weeks. No serious treatment-emergent adverse events or adverse-event-related discontinuations were observed with ruxolitinib, although the small study limits safety conclusions.
- Phase 2 randomized trial enrolled 64 adults with cutaneous lichen planus.
- Week 16 skin treatment success: 50.0% with ruxolitinib versus 21.9%.
- Clinically meaningful itch improvement occurred more frequently with ruxolitinib.
- Small sample and short controlled follow-up limit safety conclusions.
A phase 2, double-blind trial evaluated twice-daily ruxolitinib 1.5% cream against vehicle in 64 adults with predominantly cutaneous lichen planus at 19 US and Canadian sites. Participants had an Investigator’s Global Assessment (IGA) score of 3 or 4, itch scores of at least 4, and affected body surface area of 20% or less. The 16-week randomized period was followed by a 16-week open-label extension for eligible participants.
At week 16, IGA treatment success—clear or almost clear skin with at least a two-grade improvement—occurred in 50.0% of ruxolitinib recipients versus 21.9% receiving vehicle (reported response rate difference, 29.4 percentage points; 95% CI, 7.6–51.3; P=.01). A reduction of at least four points in itch score occurred in 48.4% versus 16.1%, respectively (P=.004). The abstract reports further improvement through week 32 but provides no extension response rates.
No serious treatment-emergent adverse events or discontinuations due to adverse events were observed with ruxolitinib cream. These findings support its potential as a treatment for cutaneous lichen planus, but the small sample and short controlled follow-up limit conclusions about durability and uncommon harms. The open-label extension lacked a vehicle comparator. This update is based on the abstract; full text was unavailable.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
JAMA Dermatology: Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.